Ulrich B Keller

Summary

Affiliation: Klinikum rechts der Isar
Country: Germany

Publications

  1. pmc Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck
    Alexander Hoellein
    III Medical Department, Technische Universitat Munchen, Munich, Germany
    Oncotarget 2:599-609. 2011
  2. pmc Cks1 is required for tumor cell proliferation but not sufficient to induce hematopoietic malignancies
    Susanne Kratzat
    III Medical Department, Technische Universitat Munchen, Munich, Germany
    PLoS ONE 7:e37433. 2012
  3. pmc Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival
    Julia Y Wagner
    III Medical Department, Technische Universitat Munchen, Munich, Germany
    Oncotarget 4:899-910. 2013
  4. doi request reprint Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy
    Ulrich Keller
    III Medical Department, Technische Universitat Munchen, Munich, Germany
    J Cell Mol Med 14:805-17. 2010
  5. pmc Myc suppression of Nfkb2 accelerates lymphomagenesis
    Ulrich Keller
    III Medical Department, Technische Universitat Munchen, Munich, Germany
    BMC Cancer 10:348. 2010
  6. doi request reprint Stromal pleiotrophin regulates repopulation behavior of hematopoietic stem cells
    Rouzanna Istvanffy
    III Department of Internal Medicine, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany
    Blood 118:2712-22. 2011
  7. pmc Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis
    Jennifer B Old
    Department of Biochemistry, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Mol Cancer Res 8:353-62. 2010

Collaborators

  • Christian Peschel
  • Jurgen Ruland
  • Nikolas von Bubnoff
  • Mark A Hall
  • Jonas A Nilsson
  • Robert A J Oostendorp
  • Alexander Hoellein
  • Susanne Kratzat
  • Julia Y Wagner
  • Stephanie Schoeffmann
  • Rouzanna Istvanffy
  • Steffi Graf
  • Jennifer B Old
  • Hans Jurgen Wester
  • Christoph von Schilling
  • Burkhard Schmidt
  • Klemens Scheidhauer
  • Kathleen Schwarz
  • Markus Schwaiger
  • Susanne Schreiber
  • Anna Lena Illert
  • Oliver Gorka
  • Justus Duyster
  • Cornelius Miething
  • Viktoriya Nikolova
  • Elke Pietschmann
  • Sylke Gitzelmann
  • Franziska Bock
  • Tobias Dechow
  • Stefan Wagenpfeil
  • Anja Baumgart
  • Christina Eckl
  • Baiba Vilne
  • Monika Kröger
  • Matthias Schiemann
  • Martina Rudelius
  • Anja Pickhard
  • Fabienne von Keitz
  • Henning Bier
  • Guido Piontek
  • Keiichi I Nakayama
  • John L Cleveland
  • Lisa Nilsson

Detail Information

Publications7

  1. pmc Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck
    Alexander Hoellein
    III Medical Department, Technische Universitat Munchen, Munich, Germany
    Oncotarget 2:599-609. 2011
    ..Our results demonstrate that combined targeting of EGFR and Aurora kinases represents a therapeutic means to activate cell cycle checkpoints and apoptosis in SCCHN...
  2. pmc Cks1 is required for tumor cell proliferation but not sufficient to induce hematopoietic malignancies
    Susanne Kratzat
    III Medical Department, Technische Universitat Munchen, Munich, Germany
    PLoS ONE 7:e37433. 2012
    ..Therefore, despite being associated with a poor prognosis in various malignancies, sole Cks1 expression is insufficient to induce lymphoma or a myeloproliferative disease in vivo...
  3. pmc Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival
    Julia Y Wagner
    III Medical Department, Technische Universitat Munchen, Munich, Germany
    Oncotarget 4:899-910. 2013
    ..Myeloablative anti-CD20 RIT followed by autologous stem cell infusion (ASCT) enables high radiation doses to lymphoma sites. We performed a phase I/II trial to assess feasibility and survival...
  4. doi request reprint Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy
    Ulrich Keller
    III Medical Department, Technische Universitat Munchen, Munich, Germany
    J Cell Mol Med 14:805-17. 2010
    ..After all, the success of a molecular targeted therapy is clearly determined by the significance of the targeted structure for the biology of cancer and the ability of the malignant cell to evade specific inhibition...
  5. pmc Myc suppression of Nfkb2 accelerates lymphomagenesis
    Ulrich Keller
    III Medical Department, Technische Universitat Munchen, Munich, Germany
    BMC Cancer 10:348. 2010
    ..The Rel/NF-kappaB family member NFKB2 is altered by chromosomal translocations or deletions in lymphoid malignancies and deletion of the C-terminal ankyrin domain of NF-kappaB2 augments lymphocyte proliferation...
  6. doi request reprint Stromal pleiotrophin regulates repopulation behavior of hematopoietic stem cells
    Rouzanna Istvanffy
    III Department of Internal Medicine, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany
    Blood 118:2712-22. 2011
    ..Moreover, our results support the idea that microenvironmental Ptn regulates hematopoietic regeneration through β-catenin-independent regulation of Ccnd1 and Cebpa...
  7. pmc Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis
    Jennifer B Old
    Department of Biochemistry, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Mol Cancer Res 8:353-62. 2010
    ..Collectively, these findings suggest that Cks1 targets, in addition to p27(Kip1), are critical for Myc-driven proliferation and tumorigenesis...